Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | TPI1 | P60174 | 2/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.30 |
| ▸ | PGK1 | P00558 | 1/20 | 0.30 |
| ▸ | PGK2 | P07205 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15725546 | 0.85 | FBP1 (0.41) | FBP1TPI1LPAR3LPAR1LPAR2 | |
| SCHEMBL16041590 | 0.78 | FBP1 (0.37) | FBP1TPI1LPAR3LPAR1LPAR2 | |
| SCHEMBL135753 | 0.73 | FBP1 (0.37) | FBP1TPI1LPAR3LPAR1LPAR2 | |
| SCHEMBL133396 | 0.73 | FBP1 (0.37) | FBP1TPI1LPAR3LPAR1LPAR2 | |
| SCHEMBL23777275 | 0.73 | FBP1 (0.37) | FBP1TPI1LPAR3LPAR1LPAR2 | |
| SCHEMBL3686090 | 0.73 | LPAR3 (0.43) | TPI1LPAR3LPAR1LPAR2PGK1 | |
| SCHEMBL6413988 | 0.73 | LPAR3 (0.43) | FBP1TPI1LPAR3LPAR1LPAR2 | |
| SCHEMBL22077224 | 0.72 | BTN3A1 (0.41) | — | |
| Ammonia Solution, Strong SCHEMBL5467104 | 0.71 | S1PR1 (0.36) | FBP1TPI1LPAR3LPAR1LPAR2 | |
| SCHEMBL23633124 | 0.71 | FBP1 (0.35) | FBP1TPI1LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017490-A1 | STING INHIBITORS AND THEIR THERAPEUTIC USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017490-A1 | STING INHIBITORS AND THEIR THERAPEUTIC USES | STING1, CGAS, MAVS | FBP1 2746/4885TPI1 712/4885LPAR3 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.